biostudies-literatureLeon-Ferre RANCATS NIH HHSNCI NIH HHS1135-1144https://www.ebi.ac.uk/biostudies/studies/S-EPMC10988354biostudies-literatureUnknown331(13)<h4>Importance</h4>The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant chemotherapy is unclear.<h4>Objective</h4>To study the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy but no chemotherapy.<h4>Design, setting, and participants</h4>Retrospective pooled analysis of individual patient-level data from 13 participating centers in North America (Rochester, Minnesota; Vancouver, British Columbia, Canada), Europe (Paris, Lyon, and Villejuif, France; Amsterdam and Rotterdam, the Netherlands; Milan, Padova, and GenoJAMATumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.PMC10988354P50 CA116201KL2 TR002379Kok MMichiels SCriscitiello CShimoi TJules-Clement GLambertini MLinderholm BJonas SFCurigliano GKim SBLee HJRiaz NYazaki SBataillon GYoshida MCarter JMTimmermans AMNielsen TOChia SVincent-Salomon AAndre FInternational Immuno-Oncology Biomarker Working Groupvan Deurzen CHMLinn SCSuman VJDieci MVSalgado RMartens JWMLoi SGoetz MPde Jong VLeon-Ferre RACockenpot VLeung SfalseTumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.<h4>Importance</h4>The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant chemotherapy is unclear.<h4>Objective</h4>To study the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy but no chemotherapy.<h4>Design, setting, and participants</h4>Retrospective pooled analysis of individual patient-level data from 13 participating centers in North America (Rochester, Minnesota; Vancouver, British Columbia, Canada), Europe (Paris, Lyon, and Villejuif, France; Amsterdam and Rotterdam, the Netherlands; Milan, Padova, and Geno2024-01-01T00:00:00Z2024 Apr2025-04-18T13:47:02.25Z2025-04-06T23:38:14.888ZS-EPMC109883543856383410.1001/jama.2024.3056